Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Cancer Cell|July 5, 2016
Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung CancerSunil Singhal, Pratik S Bhojnagarwala, Shaun O'Brien, et al.
JCI Insight|May 7, 2024
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient miceZainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple MyelomaShwetha H Manjunath, Adam D Cohen, Simon F Lacey, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
Blood|August 24, 2023
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapyYan Tang, Wei Liu, Siddhant Kadu, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Journal of Hematology & Oncology|April 21, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Luca Paruzzo, Vrutti Patel, et al.
Targeted Oncology|March 26, 2026
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine DynamicsNatalia A Quijano Cardé, Jin Niu, Yue Guo, et al.
Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
Pageof 7